Acute Lymphoblastic Leukemia (ALL)
The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.
Inotuzumab ozogamicin (InO) use may have quality of life benefits for patients with R/R B-cell ALL, as well as producing improved clinical outcomes.
A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.
1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence 
Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.
Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.
The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy
Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.
The site of cancer care may partially explain survival differences between children and AYAs with ALL.
Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.
Two infants with advanced acute lymphoblastic leukemia (ALL) achieved full remission following gene therapy involving modified autologous CAR-T cells.
Study results indicate that herpetic cytomegalovirus infection prior to birth subjects the child to increased odds of developing pediatric acute lymphoblastic leukemia.
Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.
Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With CancerOctober 11, 2016
Children with cancer are at risk for developing behavioral problems after diagnosis.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.
Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.
Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.
Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic LeukemiaMay 20, 2016
Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.
[Clinical Oncology in Adolescents and Young Adults] This research reviews the outcomes with chemotherapy alone and with hematopoietic stem cell transplantation in acute lymphoblastic leukemia, and examines the challenges faced in determining the best therapy for the adolescents and young adult patient population.
Anxiety and Depressive Symptoms Are Increased in Pediatric Survivors of Acute Lymphoblastic LeukemiaApril 04, 2016
Emotional distress during and after undergoing chemotherapy for ALL affects a significant percentage of children with the disease.
A subtype-specific weakness of T-cell acute lymphoblastic leukemia (T-ALL) could enable improved treatment, according to results from a a recent study using a mouse model.
Study Findings Show Possible Association Between PreLabor Cesarean Delivery and Risk for ALL in Young ChildrenMarch 16, 2016
The finding that prelabor cesarean delivery may have a correlation with acute lymphoblastic leukemia (ALL) may offer new targets for research into preventing cancer.
Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.
Pediatric survivors of ALL treated only with chemotherapy remain at an increased risk for attention problems 2 years after treatment cessation.
Abnormal breakage and chromosomal rearrangement in white blood cells result in a particularly aggressive Philadelphia chromosome-like ALL, according to a new study.
Significant bone loss in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) occurs during the first month of treatment.
Sign Up for Free e-newsletters
- Factoring in Breast Density Improves Long-Term Risk Models for Breast Cancer
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
- Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
- Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer
- In Older Women With Breast Cancer QoL May Predict 10-Year Mortality
- Screening Colonoscopy Improves CRC-Related Mortality in Veterans
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|